Oncobit™ PM
Personalized Monitoring Platform
Oncobit™ PM consists of digital PCR reagents and software for the quantitative detection of cancer markers in circulating tumor-derived DNA (ctDNA) isolated from cancer patient’s blood.
By focusing on individual cancer specific markers, Oncobit™ PM represents a radically simplified but therefore highly cost- and time efficient cancer monitoring tool for a data-driven and optimal therapy management.
Unlike traditional PCR approaches, digital PCR is a massive parallelization of PCR that allows a more sensitive and quantitative detection of cancer markers. Our assays run on existing digital PCR infrastructure and can therefore be easily implemented. Importantly, they are accompanied by our proprietary, cloud-based analytics platform, which not only provides automated data interpretation and reporting but has been trained on healthy data by machine learning for the elimination of bias and the generation of more robust results. The implementation of such a standardized data analysis is particularly critical when implementing ultrasensitive technologies in the clinical routine.
Oncobit™ PM is a platform technology that is easily scalable to any cancer characterized by so called
hotspot mutations. With an initial focus on melanoma, our portfolio includes assays for the quantification of five critical melanoma markers, BRAF V600, NRAS Q61, GNAQ Q209, GNA11 Q209, and SF3B1 R625. These assays are CE-marked under IVDR and are already being used in Switzerland for the monitoring of melanoma patients.
We have generated clinical utility data in metastatic uveal melanoma, demonstrating how Oncobit™ PM enables therapy response monitoring and prognostic assessment for progression free sruvival (PFS) and overall survival (OS) at baseline and during therapy.
Clinical Data for Uveal Melanoma
We are currently expanding our portfolio to include markers to address additional cancer types, such as
colorectal and bladder cancer.
